Logo Image
News
Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Publications
All JournalsEditorial BoardFor AuthorsYear in Review
More
Events
Frontline ForumSatellite Sessions
CME/CE
Resources
Awareness MonthThe Bispecifics NetworkNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career Center

Subscribe

  • News
  • Watch
  • Conferences
  • Publications
  • Events
  • CME/CE
  • Resources
  • Career Center
  • Subscribe
  • Adverse Effects
  • Artificial Intelligence
  • Brain Cancer
  • Breast Cancer
    • HER2-Positive Breast Cancer
    • Triple-Negative Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Esophageal Cancer
    • Pancreatic Cancer
    • Gastric Cancer
    • Liver Cancer
  • Genitourinary Cancers
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Ovarian Cancer
    • Cervical Cancer
  • Head & Neck Cancer
  • Hematologic Oncology
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Myeloproliferative Neoplasms
  • Infection
    • Vaccines
  • Leukemia
  • Lung Cancer
    • Small Cell Lung Cancer (SCLC)
    • Non-Small Cell Lung Cancer (NSCLC)
  • Lymphoma
  • Neuroendocrine Tumors
  • Oncology
  • Pediatric Cancers
  • Psycho-Oncology
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Surgery
  • Thyroid Cancer
Spotlight -
Psycho-Oncology|
Artificial Intelligence|
Career Center|
Radiation Oncology|
Surgery
Advertisement

Gokturk Maralcan

Advertisement

Articles by Gokturk Maralcan

38 [P]ostoperative [A]nalgesia and [I]nvestigating [N]arcotics in Breast Cancer Patients; Protocol BHWGI 24-01: PAIN

BySuzan Yalcin,Safa Vatansever,Berk Goktepe,Yagmur Turac Kosem,Levhi Akin,Bulent Comcali,Ahmet Dag,Gokturk Maralcan,Kazim Senol,Atilla Soran, MD, MPH
June 29th 2026

In 433 patients undergoing breast surgery, median VAS pain scores declined from 2 on day 1 to 0 by day 30, with severe pain in only 7.4% and opioid use in 2.5%, supporting nonopioid-based analgesic protocols.

Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on CancerNetwork

    1

    Rethinking HCC Surveillance and Treatment Amid a Shifting Risk Landscape

    2

    Sequencing B7-H3 and SEZ6 ADCs With DLL3 Bispecifics in SCLC

    3

    Efti Plus Pembrolizumab and RT Yields 81% 12-Month DFS in Soft Tissue Sarcoma

    4

    Testosterone Therapy Shows No Added Progression Risk in Active Surveillance PCa

    5

    Tarlatamab Maintenance Leads the Leaps Forward in Small Cell Lung Cancer

    • About
    • Advertise
    • CureToday.com
    • OncLive.com
    • OncNursingNews.com
    • TargetedOnc.com
    • Editorial
    • Contact
    • Terms and Conditions
    • Privacy
    • Do Not Sell My Personal Information
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    Brand Logo

    © 2026 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us